Your medical history, goals, and physician’s evaluation guide the plan. Here’s a clearer look at the options we can discuss in person—along with their costs and limitations.
For some patients, prescription medication can support a weight-management plan that includes nutrition and activity. Your physician will review potential benefits, side effects, contraindications, and appropriate alternatives before prescribing.
We can also discuss FDA-approved branded options when medically appropriate. Wegovy (semaglutide) and Zepbound (tirzepatide) have weight-management indications for eligible patients. Ozempic and Mounjaro are indicated for type 2 diabetes and are not FDA-approved for weight loss. The brands have different labeled uses; your physician will explain what is appropriate for you. Branded medication pricing is separate from the compounded prices above.
UNDERSTANDING THE SCIENCE
Appetite is a conversation between your body and brain.
Hormone signalsGLP-1 is involved in appetite and blood sugar regulation.
Appetite & fullnessGLP-1 receptor agonists act on pathways involved in hunger and food intake.
Support for a planMedication may make a nutrition and activity plan more manageable for eligible patients.
Semaglutide acts at GLP-1 receptors. Tirzepatide acts at both GIP and GLP-1 receptors. These medications also delay gastric emptying. This simplified explanation does not establish the safety, effectiveness, or equivalence of any compounded formulation. Responses and side effects vary.
FREE BMI HEALTH ASSESSMENT
Get your free Health Report Card.
Not sure where to start? Complete our BMI Health Assessment for a clearer starting point. See your BMI screening result, explore weight-related health topics, and bring your questions to a conversation with our care team.
Meals, schedules, preferences, and hunger all affect what feels sustainable. Talk with your care team about meal planning and habits that fit your day, with attention to nutrition and maintaining strength.
Medication is one possible part of the discussion. It does not replace nutrition, activity, or follow-up care.
Phentermine and diethylpropion are prescription appetite suppressants that may be considered for eligible patients. They act on the central nervous system and are generally used for short-term treatment alongside diet and activity changes.
A careful fit matters.
These medications can cause side effects such as increased heart rate, elevated blood pressure, and sleep problems. They are controlled substances with misuse and dependence risks and are not appropriate for everyone. Your physician reviews your health history, medications, and monitoring needs before deciding.
03 / QUESTIONS ABOUT INJECTIONS
Familiar names. Clear expectations.
B12, lipotropic injections, and “skinny shots” are often discussed alongside weight loss. They are different from GLP-1 medications, and their role and evidence should be considered separately.
Vitamin B12 injections
B12 treatment can help when a deficiency or another medical indication is present. B12 injections have not been shown to cause weight loss in people without a deficiency. Your clinician can assess whether evaluation or treatment is appropriate.
Lipotropic & “skinny shots”
These names can refer to different ingredient combinations. Evidence supporting them as weight-loss treatments is limited. These injections are not established fat-loss treatments and do not replace a personalized weight-management plan. Ask the clinic about the exact ingredients, evidence, risks, and cost before choosing an injection.
Prescription treatments require a medical evaluation. GLP-1–based medications commonly cause gastrointestinal effects such as nausea, vomiting, diarrhea, or constipation. Serious risks can include pancreatitis, gallbladder problems, dehydration-related kidney problems, and severe allergic reactions. Low blood sugar risk can increase with some diabetes medicines. Tell your physician about all medications, pregnancy or plans for pregnancy, and upcoming procedures requiring anesthesia.
FDA-approved semaglutide and tirzepatide products carry boxed warnings about thyroid C-cell tumors observed in rodents; the relevance to humans is unknown. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. This is not a complete list of risks, contraindications, or instructions. Review the prescribing information for the specific product with your physician and pharmacist. Do not combine these treatments without medical guidance.
Do not use the website or general chat for urgent symptoms, dosing instructions, or sensitive medical information. Call your medical team for individual treatment questions; seek emergency help for urgent symptoms.